BACKGROUND: Men with a BRCA2 mutation face substantial lifetime risks for the development of both breast and prostate cancer.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
INVESTIGATIONS: A male who was initially diagnosed with breast cancer at the age of 32 was was subsequently diagnosed at age 77 with both contralateral breast cancer and prostate cancer. He was found to be BRCA2 mutation carrier.
DIAGNOSIS: Hereditary multiple primary cancer in a male BRCA2 mutation carrier.
MANAGEMENT: The patient was treated with contralateral mastectomy, breast irradiation, prostate irradiation and adjuvant endocrine therapy. At age 83 he died of metastatic prostate cancer.
CONCLUSION: Our case underscores the observation that BRCA2 mutation carriers are at risk for multiple cancers, including contralateral breast cancer, and illustrates the need for current practice recommendations for the early detection of breast and prostate cancer in men with BRCA2 mutations.
Singer CF, Rappaport-Fuerhauser C, Sopik V, Narod SA. Are you the author?
Department of OB/GYN, and Comprehensive Cancer Center, Medical University of Vienna, Austria.
Reference: Clin Genet. 2014 Aug 12. Epub ahead of print.